ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2024, Vol. 16 ›› Issue (2): 102-106.

• 综述 • 上一篇    下一篇

ADA2基因变异与腺苷脱氨酶2缺乏症的研究进展

  

  • 出版日期:2024-04-25 上线日期:2024-04-25

Research progress of ADA2 gene mutation and the deficiency of adenosine deaminase 

  • Published:2024-04-25 Online:2024-04-25

摘要: 腺苷脱氨酶2缺乏症是一种罕见的常染色体隐性遗传的自身炎症性疾病,是由ADA2基因纯合或复合杂合变异导致腺苷脱氨酶2活性低下或缺乏而致病。该缺乏症主要临床表现为儿童期起病的全身性炎症、血管炎、体液免疫缺陷和血液学异常等,早期诊断困难,发病机制尚不完全清楚。全身性炎症表型患者治疗首选肿瘤坏死因子α受体拮抗剂,其次为沙利度胺。造血干细胞移植主要用于严重血液学表型患者或对肿瘤坏死因子α受体拮抗剂治疗无效患者。本文对腺苷脱氨酶2缺乏症的临床特征、人口学特征、基因型以及与临床表型相关性、可能的发病机制和诊疗策略进行阐述。

关键词: 腺苷脱氨酶2缺乏症, ADA2基因, 自身炎症性疾病, 血管炎

Abstract: Deficiency of adenosine deaminase 2 (DADA2) is a rare autosomal recessive inherited autoinflammatory disease. DADA2 is caused by homozygous or complex heterozygous mutations of ADA2 gene resulting in low or insufficient activity of adenosine deaminase 2 (ADA2). The main clinical manifestations of DADA2 in childhood include systemic inflammation,vasculitis, humoral immunodeficiency and hematological abnormalities. Early diagnosis of DADA2 is difficult, and its pathogenesis is unclear. TNF-α receptor inhibitor is the first-line treatment for patients with systemic inflammatory phenotype, followed by thalidomide. Hematopoietic stem cell transplantation (HSTC) has been used mainly in the patients with severe hematological phenotype or having no response to TNF-α receptor inhibitor treatment. In this paper, we reviewed the clinical features, demographic characteristics, genotype and its correlation with clinical phenotype, possible pathogenesis and diagnosis and treatment strategy of DADA2.

Key words:

Deficiency of adenosine deaminase 2, ADA2 gene, Autoinflammatory disease, Vasculitis